Skip to main content
. 2010 Jul 1;101(10):2220–2226. doi: 10.1111/j.1349-7006.2010.01662.x

Figure 1.

Figure 1

 SK‐BR‐3 (A) and BT‐474 (B) cells were treated with threefold serial dilutions of lapatinib ranging from 0.05 to 12.15 μmol/L for 72 h or bortezomib ranging from 1 to 243 nmol/L for 72 h or the combination ranging from 0.05 μmol/L lapatinib and 1 nmol/L bortezomib to 12.15 μmol/L lapatinib and 243 nmol/L bortezomib for 72 h. Cell viability for the lapatinib arm (L) and the combination arm (C) was assayed using Cell Counting Kit‐8 and expressed as relative to the untreated control cells. Representative results are from at least three independent occasions.